Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Expected to Rise, B. Riley Financial Analyst Says

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price target lifted by analysts at B. Riley Financial from $3.00 to $4.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s target price suggests a potential upside of 161.44% from the company’s current price.

LCTX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday. D. Boral Capital raised their target price on shares of Lineage Cell Therapeutics from $2.00 to $3.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Lineage Cell Therapeutics currently has a consensus rating of “Buy” and an average target price of $5.33.

Lineage Cell Therapeutics Price Performance

LCTX opened at $1.53 on Wednesday. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $2.09. The stock has a market cap of $381.11 million, a P/E ratio of -5.46 and a beta of 1.74. The stock’s 50 day simple moving average is $1.69 and its 200 day simple moving average is $1.68.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.00 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative net margin of 436.47% and a negative return on equity of 76.13%. The business had revenue of $6.61 million for the quarter, compared to analyst estimates of $1.96 million. Research analysts expect that Lineage Cell Therapeutics will post -0.12 EPS for the current fiscal year.

Institutional Trading of Lineage Cell Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in Lineage Cell Therapeutics in the fourth quarter valued at $25,000. Citizens Financial Group Inc. RI acquired a new position in Lineage Cell Therapeutics during the 3rd quarter worth $25,000. Red Crane Wealth Management LLC increased its position in shares of Lineage Cell Therapeutics by 3.1% in the 3rd quarter. Red Crane Wealth Management LLC now owns 511,363 shares of the company’s stock worth $864,000 after purchasing an additional 15,365 shares during the last quarter. Kestra Advisory Services LLC increased its position in shares of Lineage Cell Therapeutics by 174.7% in the 4th quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock worth $46,000 after purchasing an additional 17,647 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after purchasing an additional 18,092 shares in the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.